Pediatric Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs), By Route Of Administration (Oral, Topical, Parenteral, Others), By End-User (Hospitals, Specialty Clinics, Homecare), By Region, By Competition By Type (Bladder, Piston, Diaphragm, and Spring), By Application (Blow Out Preventers (BOP), Mud Pumps, Offshore Rigs, and Others), By Deployment (Onshore, Offshore), By Region and Competition
The Global Pediatric Drugs Market reached a valuation of USD 118.54 Billion in 2022, and it is poised for impressive growth throughout the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 5.71% up to 2028 and expected to reach USD 165.02 Billion by 2028. The pediatric drugs market represents a critical sector within the pharmaceutical industry, focused on delivering safe and efficacious treatments for infants, children, and adolescents. Meeting the healthcare needs of the younger demographic necessitates specialized medications tailored to their unique physiological and developmental requirements. The market for pediatric drugs has experienced substantial growth over time, driven by advancements in medical research, regulatory initiatives, and an increased recognition of the significance of addressing childhood health concerns.
Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have encouraged pharmaceutical enterprises to invest in pediatric drug development through incentives like exclusivity extensions and financial rewards. These initiatives have sparked heightened research and development (R&D) endeavors directed at pediatric populations. Conditions such as chronic ailments (e.g., asthma, diabetes, neurological disorders) and infectious diseases (e.g., COVID-19) have impelled pharmaceutical companies to concentrate on tailored therapies for these health challenges.
Scientific progress in genomics, pharmacology, and drug delivery has facilitated the formulation of more precise and individualized pediatric medications, thus prompting augmented investment in innovative formulations suitable for children. The pediatric drugs market's evolution persists, buoyed by regulatory drives, scientific advancements, and an enhanced awareness of the distinctive healthcare prerequisites of children.
Key Market Drivers
Rising Pediatric Population
The demographic landscape is witnessing a shift, with a notable rise in the pediatric population. By 2050, the global population aged 0-14 is projected to reach 2.2 billion according to the United Nations. This surge underscores the heightened focus on pediatric healthcare, driving the demand for medications tailored to children. Their unique physiology necessitates specialized treatments that prioritize safety and efficacy.
Increasing Incidence of Pediatric Diseases
While advancements in medicine have led to reduced mortality rates among children, the prevalence of chronic and rare diseases has escalated. Conditions such as childhood cancers, autoimmune disorders, congenital diseases, and mental health disorders are more pronounced, compelling tailored medical attention and therapies.
Key Market Challenges
Ethical and Safety Considerations
Conducting clinical trials involving minors requires careful ethical navigation due to children's vulnerability and potential difficulties in symptom expression. Balancing data acquisition and participant well-being poses a challenge.
Lack of R&D Focus
Historically, children have been underrepresented in clinical trials due to ethical concerns and logistical complexities. This scarcity impedes the availability of evidence-backed treatments designed for children's needs.
Dosing and Formulation Complexity
Pediatric patients' dynamic growth necessitates distinct approaches to dosing and drug forms compared to adults. Developing age-appropriate dosage forms and dosages is intricate and crucial to avoid incorrect dosing outcomes.
Key Market Trends
Technological Advancements
Technological breakthroughs are reshaping pediatric medicine, altering diagnosis, treatment, and drug development landscapes. Precision medicine, pharmacogenomics, digital health technologies, and artificial intelligence (AI) are revolutionizing pediatric healthcare by enhancing treatment customization, real-world evidence collection, and drug discovery.
Segmental Insights
Type Insights
The Respiratory Disorder Drugs segment is the dominant segment, reflecting the prevalence of conditions like asthma and bronchitis in pediatric populations. The rising exposure to allergens, infections, and environmental factors contributes to respiratory disorders' prominence.
End-Use Insights
Hospitals are the major end-users due to their expertise in offering tailored pediatric care. Specialized departments and diagnostic tools position hospitals as the primary source of comprehensive pediatric treatment.
Regional Insights
North America, with its robust pharmaceutical industry, research institutions, and favorable regulatory framework, drives the pediatric drugs market. Initiatives like the Pediatric Research Equity Act (PREA) and clinical trial infrastructure contribute to growth.
The forecasted period presents opportunities for growth and innovation in the pediatric drugs market. The industry's response to ethical concerns, formulation complexity, and unique pediatric needs, coupled with advancements in precision medicine, digital health, collaboration, and rare disease treatment, can shape the future of pediatric healthcare positively. By embracing these challenges and capitalizing on opportunities, the pharmaceutical sector can contribute significantly to pediatric well-being and healthcare advancement.
Key Market Players
In this report, the Global Pediatric Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Drugs Market.
Available Customizations:
Global Pediatric Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have encouraged pharmaceutical enterprises to invest in pediatric drug development through incentives like exclusivity extensions and financial rewards. These initiatives have sparked heightened research and development (R&D) endeavors directed at pediatric populations. Conditions such as chronic ailments (e.g., asthma, diabetes, neurological disorders) and infectious diseases (e.g., COVID-19) have impelled pharmaceutical companies to concentrate on tailored therapies for these health challenges.
Scientific progress in genomics, pharmacology, and drug delivery has facilitated the formulation of more precise and individualized pediatric medications, thus prompting augmented investment in innovative formulations suitable for children. The pediatric drugs market's evolution persists, buoyed by regulatory drives, scientific advancements, and an enhanced awareness of the distinctive healthcare prerequisites of children.
Key Market Drivers
Rising Pediatric Population
The demographic landscape is witnessing a shift, with a notable rise in the pediatric population. By 2050, the global population aged 0-14 is projected to reach 2.2 billion according to the United Nations. This surge underscores the heightened focus on pediatric healthcare, driving the demand for medications tailored to children. Their unique physiology necessitates specialized treatments that prioritize safety and efficacy.
Increasing Incidence of Pediatric Diseases
While advancements in medicine have led to reduced mortality rates among children, the prevalence of chronic and rare diseases has escalated. Conditions such as childhood cancers, autoimmune disorders, congenital diseases, and mental health disorders are more pronounced, compelling tailored medical attention and therapies.
Key Market Challenges
Ethical and Safety Considerations
Conducting clinical trials involving minors requires careful ethical navigation due to children's vulnerability and potential difficulties in symptom expression. Balancing data acquisition and participant well-being poses a challenge.
Lack of R&D Focus
Historically, children have been underrepresented in clinical trials due to ethical concerns and logistical complexities. This scarcity impedes the availability of evidence-backed treatments designed for children's needs.
Dosing and Formulation Complexity
Pediatric patients' dynamic growth necessitates distinct approaches to dosing and drug forms compared to adults. Developing age-appropriate dosage forms and dosages is intricate and crucial to avoid incorrect dosing outcomes.
Key Market Trends
Technological Advancements
Technological breakthroughs are reshaping pediatric medicine, altering diagnosis, treatment, and drug development landscapes. Precision medicine, pharmacogenomics, digital health technologies, and artificial intelligence (AI) are revolutionizing pediatric healthcare by enhancing treatment customization, real-world evidence collection, and drug discovery.
Segmental Insights
Type Insights
The Respiratory Disorder Drugs segment is the dominant segment, reflecting the prevalence of conditions like asthma and bronchitis in pediatric populations. The rising exposure to allergens, infections, and environmental factors contributes to respiratory disorders' prominence.
End-Use Insights
Hospitals are the major end-users due to their expertise in offering tailored pediatric care. Specialized departments and diagnostic tools position hospitals as the primary source of comprehensive pediatric treatment.
Regional Insights
North America, with its robust pharmaceutical industry, research institutions, and favorable regulatory framework, drives the pediatric drugs market. Initiatives like the Pediatric Research Equity Act (PREA) and clinical trial infrastructure contribute to growth.
The forecasted period presents opportunities for growth and innovation in the pediatric drugs market. The industry's response to ethical concerns, formulation complexity, and unique pediatric needs, coupled with advancements in precision medicine, digital health, collaboration, and rare disease treatment, can shape the future of pediatric healthcare positively. By embracing these challenges and capitalizing on opportunities, the pharmaceutical sector can contribute significantly to pediatric well-being and healthcare advancement.
Key Market Players
- BioMarin
- Horizon Therapeutics plc
- Gilead Sciences Inc.
- Sumitomo Pharma Co., Ltd.
- Jazz Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- Abbott
- F. Hoffman La Roche, Ltd.
- Boehringer Ingelheim International GmbH
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer, Inc.
In this report, the Global Pediatric Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Pediatric Drugs Market, By Type:
- Respiratory Disorder Drugs
- Autoimmune Disorder Drugs
- Gastrointestinal Drugs
- Cardiovascular Drugs
- Pediatric Drugs Market, By Route Of Administration:
- Oral
- Topical
- Parenteral
- Others
- Pediatric Drugs Market, By End-Use:
- Hospitals
- Specialty Clinics
- Homecare
- Pediatric Drugs Market, By Region:
- North America
- Asia-Pacific
- Europe
- Middle East & Africa
- South America
Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Drugs Market.
Available Customizations:
Global Pediatric Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. IMPACT OF COVID-19 ON GLOBAL PEDIATRIC DRUGS MARKET
4. VOICE OF CUSTOMER
5. EXECUTIVE SUMMARY
6. GLOBAL PHAGE THERAPY MARKET OVERVIEW
7. GLOBAL PEDIATRIC DRUGS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs)
7.2.2. By Route Of Administration (Oral, Topical, Parenteral, Others)
7.2.3. By End User (Hospitals, Specialty Clinics, Homecare)
7.2.4. By Company (2022)
7.2.5. By Region
7.3. Market Map
7.3.1. By Type
7.3.2. By Route Of Administration
7.3.3. By End User
8. NORTH AMERICA PEDIATRIC DRUGS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Route Of Administration
8.2.3. By End User
8.2.4. By Country
8.3. Policy & Regulatory Landscape
8.4. North America: Country Analysis
8.4.1. United States Pediatric Drugs Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Type
8.4.1.2.2. By Route Of Administration
8.4.1.2.3. By End User
8.4.2. Mexico Pediatric Drugs Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Type
8.4.2.2.2. By Route Of Administration
8.4.2.2.3. By End User
8.4.3. Canada Pediatric Drugs Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Type
8.4.3.2.2. By Route Of Administration
8.4.3.2.3. By End User
9. EUROPE PEDIATRIC DRUGS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Route Of Administration
9.2.3. By End User
9.2.4. By Country
9.3. Policy & Regulatory Landscape
9.4. Europe: Country Analysis
9.4.1. France Pediatric Drugs Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Type
9.4.1.2.2. By Route Of Administration
9.4.1.2.3. By End User
9.4.2. Germany Pediatric Drugs Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Type
9.4.2.2.2. By Route Of Administration
9.4.2.2.3. By End User
9.4.3. United Kingdom Pediatric Drugs Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Type
9.4.3.2.2. By Route Of Administration
9.4.3.2.3. By End User
9.4.4. Italy Pediatric Drugs Market Outlook
9.4.4.1. Market Size & Forecast
9.4.4.1.1. By Value
9.4.4.2. Market Share & Forecast
9.4.4.2.1. By Type
9.4.4.2.2. By Route Of Administration
9.4.4.2.3. By End User
9.4.5. Spain Pediatric Drugs Market Outlook
9.4.5.1. Market Size & Forecast
9.4.5.1.1. By Value
9.4.5.2. Market Share & Forecast
9.4.5.2.1. By Type
9.4.5.2.2. By Route Of Administration
9.4.5.2.3. By End User
10. ASIA-PACIFIC PEDIATRIC DRUGS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Route Of Administration
10.2.3. By End User
10.2.4. By Country
10.3. Policy & Regulatory Landscape
10.4. Asia-Pacific: Country Analysis
10.4.1. China Pediatric Drugs Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Type
10.4.1.2.2. By Route Of Administration
10.4.1.2.3. By End User
10.4.2. India Pediatric Drugs Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Type
10.4.2.2.2. By Route Of Administration
10.4.2.2.3. By End User
10.4.3. Japan Pediatric Drugs Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Type
10.4.3.2.2. By Route Of Administration
10.4.3.2.3. By End User
10.4.4. South Korea Pediatric Drugs Market Outlook
10.4.4.1. Market Size & Forecast
10.4.4.1.1. By Value
10.4.4.2. Market Share & Forecast
10.4.4.2.1. By Type
10.4.4.2.2. By Route Of Administration
10.4.4.2.3. By End User
10.4.5. Australia Pediatric Drugs Market Outlook
10.4.5.1. Market Size & Forecast
10.4.5.1.1. By Value
10.4.5.2. Market Share & Forecast
10.4.5.2.1. By Type
10.4.5.2.2. By Route Of Administration
10.4.5.2.3. By End User
11. SOUTH AMERICA PEDIATRIC DRUGS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type
11.2.2. Route Of Administration
11.2.3. By End User
11.2.4. By Country
11.3. Policy & Regulatory Landscape
11.4. South America: Country Analysis
11.4.1. Brazil Pediatric Drugs Market Outlook
11.4.1.1. Market Size & Forecast
11.4.1.1.1. By Value
11.4.1.2. Market Share & Forecast
11.4.1.2.1. By Type
11.4.1.2.2. By Route Of Administration
11.4.1.2.3. By End User
11.4.2. Argentina Pediatric Drugs Market Outlook
11.4.2.1. Market Size & Forecast
11.4.2.1.1. By Value
11.4.2.2. Market Share & Forecast
11.4.2.2.1. By Type
11.4.2.2.2. By Route Of Administration
11.4.2.2.3. By End User
11.4.3. Colombia Pediatric Drugs Market Outlook
11.4.3.1. Market Size & Forecast
11.4.3.1.1. By Value
11.4.3.2. Market Share & Forecast
11.4.3.2.1. By Type
11.4.3.2.2. By Route Of Administration
11.4.3.2.3. By End User
12. MIDDLE EAST AND AFRICA PEDIATRIC DRUGS MARKET OUTLOOK
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Type
12.2.2. By Route Of Administration
12.2.3. By End User
12.2.4. By Country
12.3. Policy & Regulatory Landscape
12.4. MEA: Country Analysis
12.4.1. South Africa Pediatric Drugs Market Outlook
12.4.1.1. Market Size & Forecast
12.4.1.1.1. By Value
12.4.1.2. Market Share & Forecast
12.4.1.2.1. By Type
12.4.1.2.2. Route Of Administration
12.4.1.2.3. By End User
12.4.2. Saudi Arabia Pediatric Drugs Market Outlook
12.4.2.1. Market Size & Forecast
12.4.2.1.1. By Value
12.4.2.2. Market Share & Forecast
12.4.2.2.1. By Type
12.4.2.2.2. By Route Of Administration
12.4.2.2.3. By End User
12.4.3. UAE Pediatric Drugs Market Outlook
12.4.3.1. Market Size & Forecast
12.4.3.1.1. By Value
12.4.3.2. Market Share & Forecast
12.4.3.2.1. By Type
12.4.3.2.2. By Route Of Administration
12.4.3.2.3. By End User
13. MARKET DYNAMICS
13.1. Drivers
13.2. Challenges
14. MARKET TRENDS & DEVELOPMENTS
15. PORTER’S FIVE FORCE’S ANALYSIS
16. GLOBAL PEDIATRIC DRUGS MARKET: SWOT ANALYSIS
17. LIST OF COMMERCIALLY AVAILABLE PHAGE TYPES FOR ANIMAL HEALTH
18. COMPETITIVE LANDSCAPE
18.1. Business Overview
18.2. Company Snapshot
18.3. Types & Services
18.4. Financials (In case of listed companies)
18.5. Recent Developments
18.6. SWOT Analysis
18.6.1. BioMarin
18.6.2. Horizon Therapeutics plc
18.6.3. Gilead Sciences Inc.
18.6.4. Sumitomo Pharma Co., Ltd.
18.6.5. Jazz Pharmaceuticals, Inc.
18.6.6. GlaxoSmithKline plc.
18.6.7. Abbott
18.6.8. F. Hoffman La Roche, Ltd.
18.6.9. Boehringer Ingelheim International GmbH
18.6.10. Johnson & Johnson Services, Inc.
18.6.11. Novartis AG
18.6.12. Pfizer, Inc.
19. STRATEGIC RECOMMENDATIONS
20. ABOUT US & DISCLAIMER
2. RESEARCH METHODOLOGY
3. IMPACT OF COVID-19 ON GLOBAL PEDIATRIC DRUGS MARKET
4. VOICE OF CUSTOMER
5. EXECUTIVE SUMMARY
6. GLOBAL PHAGE THERAPY MARKET OVERVIEW
7. GLOBAL PEDIATRIC DRUGS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs)
7.2.2. By Route Of Administration (Oral, Topical, Parenteral, Others)
7.2.3. By End User (Hospitals, Specialty Clinics, Homecare)
7.2.4. By Company (2022)
7.2.5. By Region
7.3. Market Map
7.3.1. By Type
7.3.2. By Route Of Administration
7.3.3. By End User
8. NORTH AMERICA PEDIATRIC DRUGS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Route Of Administration
8.2.3. By End User
8.2.4. By Country
8.3. Policy & Regulatory Landscape
8.4. North America: Country Analysis
8.4.1. United States Pediatric Drugs Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Type
8.4.1.2.2. By Route Of Administration
8.4.1.2.3. By End User
8.4.2. Mexico Pediatric Drugs Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Type
8.4.2.2.2. By Route Of Administration
8.4.2.2.3. By End User
8.4.3. Canada Pediatric Drugs Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Type
8.4.3.2.2. By Route Of Administration
8.4.3.2.3. By End User
9. EUROPE PEDIATRIC DRUGS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Route Of Administration
9.2.3. By End User
9.2.4. By Country
9.3. Policy & Regulatory Landscape
9.4. Europe: Country Analysis
9.4.1. France Pediatric Drugs Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Type
9.4.1.2.2. By Route Of Administration
9.4.1.2.3. By End User
9.4.2. Germany Pediatric Drugs Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Type
9.4.2.2.2. By Route Of Administration
9.4.2.2.3. By End User
9.4.3. United Kingdom Pediatric Drugs Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Type
9.4.3.2.2. By Route Of Administration
9.4.3.2.3. By End User
9.4.4. Italy Pediatric Drugs Market Outlook
9.4.4.1. Market Size & Forecast
9.4.4.1.1. By Value
9.4.4.2. Market Share & Forecast
9.4.4.2.1. By Type
9.4.4.2.2. By Route Of Administration
9.4.4.2.3. By End User
9.4.5. Spain Pediatric Drugs Market Outlook
9.4.5.1. Market Size & Forecast
9.4.5.1.1. By Value
9.4.5.2. Market Share & Forecast
9.4.5.2.1. By Type
9.4.5.2.2. By Route Of Administration
9.4.5.2.3. By End User
10. ASIA-PACIFIC PEDIATRIC DRUGS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Route Of Administration
10.2.3. By End User
10.2.4. By Country
10.3. Policy & Regulatory Landscape
10.4. Asia-Pacific: Country Analysis
10.4.1. China Pediatric Drugs Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Type
10.4.1.2.2. By Route Of Administration
10.4.1.2.3. By End User
10.4.2. India Pediatric Drugs Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Type
10.4.2.2.2. By Route Of Administration
10.4.2.2.3. By End User
10.4.3. Japan Pediatric Drugs Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Type
10.4.3.2.2. By Route Of Administration
10.4.3.2.3. By End User
10.4.4. South Korea Pediatric Drugs Market Outlook
10.4.4.1. Market Size & Forecast
10.4.4.1.1. By Value
10.4.4.2. Market Share & Forecast
10.4.4.2.1. By Type
10.4.4.2.2. By Route Of Administration
10.4.4.2.3. By End User
10.4.5. Australia Pediatric Drugs Market Outlook
10.4.5.1. Market Size & Forecast
10.4.5.1.1. By Value
10.4.5.2. Market Share & Forecast
10.4.5.2.1. By Type
10.4.5.2.2. By Route Of Administration
10.4.5.2.3. By End User
11. SOUTH AMERICA PEDIATRIC DRUGS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type
11.2.2. Route Of Administration
11.2.3. By End User
11.2.4. By Country
11.3. Policy & Regulatory Landscape
11.4. South America: Country Analysis
11.4.1. Brazil Pediatric Drugs Market Outlook
11.4.1.1. Market Size & Forecast
11.4.1.1.1. By Value
11.4.1.2. Market Share & Forecast
11.4.1.2.1. By Type
11.4.1.2.2. By Route Of Administration
11.4.1.2.3. By End User
11.4.2. Argentina Pediatric Drugs Market Outlook
11.4.2.1. Market Size & Forecast
11.4.2.1.1. By Value
11.4.2.2. Market Share & Forecast
11.4.2.2.1. By Type
11.4.2.2.2. By Route Of Administration
11.4.2.2.3. By End User
11.4.3. Colombia Pediatric Drugs Market Outlook
11.4.3.1. Market Size & Forecast
11.4.3.1.1. By Value
11.4.3.2. Market Share & Forecast
11.4.3.2.1. By Type
11.4.3.2.2. By Route Of Administration
11.4.3.2.3. By End User
12. MIDDLE EAST AND AFRICA PEDIATRIC DRUGS MARKET OUTLOOK
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Type
12.2.2. By Route Of Administration
12.2.3. By End User
12.2.4. By Country
12.3. Policy & Regulatory Landscape
12.4. MEA: Country Analysis
12.4.1. South Africa Pediatric Drugs Market Outlook
12.4.1.1. Market Size & Forecast
12.4.1.1.1. By Value
12.4.1.2. Market Share & Forecast
12.4.1.2.1. By Type
12.4.1.2.2. Route Of Administration
12.4.1.2.3. By End User
12.4.2. Saudi Arabia Pediatric Drugs Market Outlook
12.4.2.1. Market Size & Forecast
12.4.2.1.1. By Value
12.4.2.2. Market Share & Forecast
12.4.2.2.1. By Type
12.4.2.2.2. By Route Of Administration
12.4.2.2.3. By End User
12.4.3. UAE Pediatric Drugs Market Outlook
12.4.3.1. Market Size & Forecast
12.4.3.1.1. By Value
12.4.3.2. Market Share & Forecast
12.4.3.2.1. By Type
12.4.3.2.2. By Route Of Administration
12.4.3.2.3. By End User
13. MARKET DYNAMICS
13.1. Drivers
13.2. Challenges
14. MARKET TRENDS & DEVELOPMENTS
15. PORTER’S FIVE FORCE’S ANALYSIS
16. GLOBAL PEDIATRIC DRUGS MARKET: SWOT ANALYSIS
17. LIST OF COMMERCIALLY AVAILABLE PHAGE TYPES FOR ANIMAL HEALTH
18. COMPETITIVE LANDSCAPE
18.1. Business Overview
18.2. Company Snapshot
18.3. Types & Services
18.4. Financials (In case of listed companies)
18.5. Recent Developments
18.6. SWOT Analysis
18.6.1. BioMarin
18.6.2. Horizon Therapeutics plc
18.6.3. Gilead Sciences Inc.
18.6.4. Sumitomo Pharma Co., Ltd.
18.6.5. Jazz Pharmaceuticals, Inc.
18.6.6. GlaxoSmithKline plc.
18.6.7. Abbott
18.6.8. F. Hoffman La Roche, Ltd.
18.6.9. Boehringer Ingelheim International GmbH
18.6.10. Johnson & Johnson Services, Inc.
18.6.11. Novartis AG
18.6.12. Pfizer, Inc.
19. STRATEGIC RECOMMENDATIONS
20. ABOUT US & DISCLAIMER
